Project description:Comprehensive expression profiling of disseminated neuroblastoma with favorable and unfavorable outcome using SAGE. Results provide insight into the molecular pathogenesis of spontaneous regression and progression of metastatic neuroblastoma and may be used for improving risk estimation of patients with disseminated neuroblastoma. Keywords: gene expression SAGE-based, neuroblastoma, primary tumor, disseminated disease Samples analyzed: 9 (stage 4S neuroblastoma: n=5, stage 4 neuroblastoma: n=3, neuroblastoma cell line: n=1)
Project description:Comprehensive expression profiling of disseminated neuroblastoma with favorable and unfavorable outcome using SAGE. Results provide insight into the molecular pathogenesis of spontaneous regression and progression of metastatic neuroblastoma and may be used for improving risk estimation of patients with disseminated neuroblastoma. Keywords: gene expression SAGE-based, neuroblastoma, primary tumor, disseminated disease
Project description:Pediatric-type low-grade gliomas (PLGG) are the most common central nervous system (CNS) tumor in children. Many are indolent and have excellent outcomes, however a major cause of morbidity and mortality can occur when tumors spread throughout the CNS. To better understand this rare and difficult-to-treat entity, as well as the underlying processes driving dissemination in CNS tumors, we assembled a large international cohort (n=269) of patients with disseminated PLGG with detailed clinical and molecular characterization. We identified three subgroups of patients based on the temporal and spatial distribution of dissemination. Tumors with diffuse leptomeningeal spread and those occurring in infants had the worst clinical outcomes. The genetics overlapped substantially with those in non-disseminated PLGG, suggesting that non-genetic mechanisms are an important contributor to dissemination. Therapeutically, targeted MAPK-pathway inhibition was more effective than conventional chemotherapy as first or second-line treatment. In sum, this clinical cohort increases our understanding of this rare disease, provides insights for improving patient care, and directs future study.